Compare PLNT & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLNT | STVN |
|---|---|---|
| Founded | 1992 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Containers/Packaging |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 7.4B |
| IPO Year | 2015 | 2021 |
| Metric | PLNT | STVN |
|---|---|---|
| Price | $105.85 | $21.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 2 |
| Target Price | ★ $118.42 | $23.75 |
| AVG Volume (30 Days) | ★ 1.3M | 246.8K |
| Earning Date | 02-24-2026 | 11-06-2025 |
| Dividend Yield | N/A | ★ 0.29% |
| EPS Growth | ★ 31.23 | 19.61 |
| EPS | ★ 2.44 | 0.60 |
| Revenue | $1,202,700,000.00 | ★ $1,373,219,524.00 |
| Revenue This Year | $21.43 | $8.42 |
| Revenue Next Year | $11.05 | $8.77 |
| P/E Ratio | $42.77 | ★ $36.42 |
| Revenue Growth | ★ 14.63 | 6.97 |
| 52 Week Low | $87.72 | $17.81 |
| 52 Week High | $114.47 | $28.00 |
| Indicator | PLNT | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 43.99 | 53.48 |
| Support Level | $103.49 | $20.09 |
| Resistance Level | $110.53 | $21.91 |
| Average True Range (ATR) | 2.44 | 0.65 |
| MACD | -0.84 | 0.23 |
| Stochastic Oscillator | 36.59 | 87.96 |
Planet Fitness Inc is a franchisor and operator of fitness centers in the United States. The company's reportable segments are Franchise, Corporate-owned stores, and Equipment. Franchise segment includes operations related to its franchising business in the United States, Puerto Rico, Canada, Panama, Mexico and Australia, Corporate-owned stores segment includes operations with respect to all corporate-owned stores throughout the United States and Canada, and The Equipment segment includes the sale of equipment to franchisee-owned stores in the U.S. The firm generates a majority of its revenue from the Corporate-owned stores segment.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.